Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Change in Accured Expenses: 2010-2018

Historic Change in Accured Expenses for Ani Pharmaceuticals (ANIP) over the last 8 years, with Sep 2018 value amounting to $1.0 million.

  • Ani Pharmaceuticals' Change in Accured Expenses fell 43.14% to $1.0 million in Q3 2018 from the same period last year, while for Sep 2018 it was $174,000, marking a year-over-year increase of 74.00%. This contributed to the annual value of $644,000 for FY2017, which is 31.49% down from last year.
  • Latest data reveals that Ani Pharmaceuticals reported Change in Accured Expenses of $1.0 million as of Q3 2018, which was up 236.72% from -$749,000 recorded in Q2 2018.
  • Over the past 5 years, Ani Pharmaceuticals' Change in Accured Expenses peaked at $1.8 million during Q3 2017, and registered a low of -$1.9 million during Q4 2015.
  • Its 3-year average for Change in Accured Expenses is $266,182, with a median of $1.0 million in 2018.
  • In the last 5 years, Ani Pharmaceuticals' Change in Accured Expenses crashed by 523.08% in 2015 and then spiked by 45,125.00% in 2017.
  • Quarterly analysis of 5 years shows Ani Pharmaceuticals' Change in Accured Expenses stood at -$630,000 in 2014, then crashed by 198.57% to -$1.9 million in 2015, then increased by 8.88% to -$1.7 million in 2016, then skyrocketed by 31.74% to -$1.2 million in 2017, then slumped by 43.14% to $1.0 million in 2018.
  • Its Change in Accured Expenses was $1.0 million in Q3 2018, compared to -$749,000 in Q2 2018 and $1.1 million in Q1 2018.